Skip to content

Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen

To Peel or Not to Peel: Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03927430
Enrollment
40
Registered
2019-04-25
Start date
2019-01-01
Completion date
2019-03-01
Last updated
2019-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Related Macular Degeneration, Epiretinal Membrane, Macular Holes

Brief summary

Surgical outcome of patients with macular drusen and co-existing abnormalities of the vitreoretinal interface, who routinely undergo pars plana vitrectomy with membrane peeling, is evaluated. Best corrected visual acuity as well as optical coherence tomography data are compared at baseline and last follow up. The rate of development of choroidal neovascularization postoperatively is noted.

Interventions

PROCEDUREpars plana vitrectomy with membrane peeling

23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade

Sponsors

Klinikum Chemnitz gGmbH
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. participants diagnosed with ERM or FTMH and co-existing macular drusen; 2. undergone pars plana vitrectomy with ILM and epiretinale membrane peeling; 3. SD-OCT at the initial visit and at last follow up visit with image quality score \>30; 4. no evidence of CNV on initial fluorescein angiography (FA).

Exclusion criteria

1. history of other macular disease, severe non-proliferative or proliferative diabetic retinopathy, other retinal vascular diseases, glaucoma, myopic retinopathy, or other diseases interfering with OCT images in any one of the eyes; 2. active CNV or history of CNV

Design outcomes

Primary

MeasureTime frameDescription
number of patients with CNVlast visit, in common 6 months postoperativelynumber of patients with CNV (choroidal neovascularization) development

Secondary

MeasureTime frameDescription
BCVAlast visit, in common 6 months postoperativelybest corrected visual acuity
incidence of central retinal atrophylast visit, in common 6 months postoperativelydevelopment of central retinal atrophy on OCT

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026